NVAX — Novavax, Inc. stock price, charts and financials

Latest market price

7.66

+0.25+3.37%

Overview Short InterestFilings

NVAXQT47Novavax, Inc.·NASDAQ

Overview Short InterestFilings

7.66+3.37%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	1.50%	Shs Outstand	164.44M	Perf Week	3.93%

Market Cap	1.26B	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	141.47M	Perf Month	-18.07%

Enterprise Value	762.60M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	30.98%	Perf Quarter	-4.61%

Income	-86.00M	P/S	2.11	EPS this Y	22.35%	Inst Trans	-	Short Ratio	9.11	Perf Half Y	-11.85%

Sales	596.00M	P/B	-	EPS next Y	42.04%	ROA	-8.42%	Short Interest	43.82M	Perf YTD	13.99%

Book/sh	-0.88	P/C	1.59	EPS next 5Y	-	ROE	89.73%	52W High	11.97 -36.01%	Perf Year	16.77%

Cash/sh	4.80	P/FCF	-	EPS past 3/5Y	-	ROIC	-9.50%	52W Low	6.20 23.55%	Perf 3Y	-6.59%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.11% 119.58%	Gross Margin	84.64%	Volatility	3.66% 4.14%	Perf 5Y	-95.72%

Dividend TTM	-	EV/Sales	1.28	EPS Y/Y TTM	51.22%	Oper. Margin	-11.19%	ATR (14)	0.39	Perf 10Y	-94.75%

Dividend Ex-Date	-	Quick Ratio	2.45	Sales Y/Y TTM	-12.61%	Profit Margin	-14.73%	RSI (14)	39.23	Recom	2.39

Dividend Gr. 3/5Y	-	Current Ratio	2.48	EPS Q/Q	-102.05%	SMA20	-5.12%	Beta	2.46	Target Price	18.00

Payout	0.00%	Debt/Eq	0.58	Sales Q/Q	-79.01%	SMA50	-14.14%	Rel Volume	0.68	Prev Close	7.41

Employees	749	LT Debt/Eq	-1.92	Earnings	Aug 06	SMA200	-9.43%	Avg Volume	4.77M	Price	7.66

IPO Date	Dec 05, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	75.18% 74.82%	Net Debt/EBITDA	-1.58	Volume	3,239,403	Change	3.37%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-24-25	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-23-25	Reiterated	HC Wainwright & Co.	Buy	$19 → $11
Aug-20-25	Downgrade	B of A Securities	Neutral → Underperform
Nov-18-24	Reiterated	B.Riley Financial	Buy	$22
Oct-16-24	Reiterated	Jefferies	Buy	$25
Oct-16-24	Reiterated	Bank of America Securities		$14
Jul-30-24	Downgrade	JP Morgan	Neutral → Underweight
Jul-19-24	Reiterated	Jefferies	Buy
May-10-24	Upgrade	B of A Securities	Underperform → Neutral
Aug-09-23	Upgrade	B. Riley Securities	Neutral → Buy

Latest News

Jul-30-26

Jul-30-2607:00AM

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026prnewswire.com

Jul-28-26

Jul-28-2611:13PM

Novavax: The Beaten-Down COVID-19 DarlingSeekingAlpha

06:45PM

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Knowzacks.com

Jul-22-26

Jul-22-2610:01AM

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Knowzacks.com

Jul-20-26

Jul-20-2606:46PM

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Notezacks.com

Jul-14-26

Jul-14-2606:45PM

Novavax (NVAX) Stock Sinks As Market Gains: Here's Whyzacks.com

Jul-10-26

Jul-10-2602:18PM

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataYahoo

Jul-08-26

Jul-08-2606:46PM

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insightszacks.com

Jul-07-26

Jul-07-2610:01AM

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on Itzacks.com

Jun-23-26

Jun-23-2608:21AM

Moderna: The Comeback Is Now In Full SwingSeekingAlpha

Jun-18-26

Jun-18-2609:45PM

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowYahoo

Jun-16-26

Jun-16-2607:21PM

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?Yahoo

06:33PM

A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The PackYahoo

Jun-12-26

Jun-12-2609:45PM

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeYahoo

Company

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	596	1,123	682	556	1,599	198	22	19	34
Cost of Goods Sold Incl. D&A	91	71	203	344	903	0	0	114	0
Gross Profit	505	1,052	479	213	696	198	22	-95	34
Selling, General and Administrative Excl. Other	129	150	337	469	489	298	145	34	34
Research and Development	345	337	391	738	1,235	2,535	747	114	174
Other Operating Expense	97	2	0	-428	-383	-949	-453	0	0
Operating Income	-66	563	-249	-567	-645	-1,687	-417	-121	-174
Interest Expense	12	23	20	14	20	21	15	14	12
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-8	-99	92	38	11	-7	14	1	1
Net Income Before Taxes	-87	442	-177	-543	-654	-1,715	-418	-133	-185
Income Taxes	1	2	11	2	4	29	0	0	1
Consolidated Net Income	-86	440	-187	-545	-658	-1,744	-418	-130	-185
Net Income From Continuing Operations	-86	440	-187	-545	-658	-1,744	-418	-133	-185
Net Income	-86	440	-187	-545	-658	-1,744	-418	-130	-185
EPS (Recurring)	-0.54	2.72	-1.23	-5.41	-8.42	-23.44	-7.43	-5.40	-9.99
EPS (Basic, Before Extraordinaries)	-0.54	2.72	-1.23	-5.41	-8.42	-23.44	-7.43	-5.40	-9.99
EPS (Diluted)	-0.60	2.54	-1.23	-5.41	-8.42	-23.44	-7.43	-5.40	-9.99
EBITDA	-42	492	-108	-487	-605	-1,681	-398	-113	-163
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	2.65	—	—	—	—	—	—	—
Price To Sales Ratio	2.09	0.97	1.79	0.87	0.50	53.47	293.98	5.03	19.48
Gross Margin	84.73	93.68	70.23	38.31	43.53	100.00	100.00	-500.00	100.00
Operating Margin	-11.07	50.13	-36.51	-101.98	-40.34	-852.02	-1,895.45	-636.84	-511.76
Net Margin	-14.43	39.18	-27.42	-98.02	-41.15	-880.81	-1,900.00	-684.21	-544.12
Shares Outstanding	163	162	152	101	78	74	58	24	18
Market Capitalization	1,249	1,089	1,222	485	802	10,587	6,468	96	662
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
DOUGLAS RICHARD	Director	Jun 20 '26	Option Exercise	18,880	73,220	Jun 23
Rodgers Richard J	Director	Jun 20 '26	Option Exercise	18,880	47,370	Jun 23
MOTT DAVID M	Director	Jun 20 '26	Option Exercise	18,880	79,770	Jun 23
King Rachel K.	Director	Jun 20 '26	Option Exercise	18,880	44,070	Jun 23
MCGLYNN MARGARET G	Director	Jun 20 '26	Option Exercise	18,880	44,468	Jun 23
Alton Gregg H	Director	Jun 20 '26	Option Exercise	18,880	47,685	Jun 23
Newton Charles W.	Director	Apr 25 '26	Option Exercise	9,520	9,520	Apr 28
Shiver John W.	Director	Mar 10 '26	Option Exercise	7,947	7,947	Mar 12
Kelly James Patrick	EVP, CFO and Treasurer	Mar 07 '26	Option Exercise	12,223	136,503	Mar 09
Casey Mark J	EVP, Chief Legal Officer	Mar 03 '26	Option Exercise	41,500	101,445	Mar 05
Kelly James Patrick	EVP, CFO and Treasurer	Mar 03 '26	Option Exercise	43,167	145,130	Mar 05
Jacobs John C	President and CEO	Mar 03 '26	Option Exercise	150,167	264,130	Mar 05
O'Hara Elaine	EVP, Chief Strategy Officer	Mar 03 '26	Option Exercise	56,334	157,071	Mar 05
Draghia-Akli Ruxandra	EVP, Research & Development	Mar 03 '26	Option Exercise	26,667	34,876	Mar 05
O'Hara Elaine	EVP, Chief Strategy Officer	Mar 01 '26	Option Exercise	59,600	111,706	Mar 03

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.